ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Mammography’s Best Role Is Screening, Kopans Assert

March 18, 1994

Politics May Play Role In FDA’s Avastin Decision

May 27, 2011

National Comprehensive Center Network, Quintiles Oncology, To Collaborate On Trials

March 5, 1999

In Brief: Hew Approves Patent Request From U. Arizona; Califano Still Pondering Bioassay Program Fate

September 1, 1978

Bill Would Improve Quality Of Care, Close Gaps in Services, Supporters Say. Sen. Arlen Specter to NIH Advocates: “Be More Politically Active;” Asks NCI For “A Winning Strategy.”

May 26, 2006

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011